Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide.
The United States Patent and Trademark Office (USPTO) has granted the company US Patent No 12,351,653, which provides protection for certepetide through March 2040, with the possibility of a patent term extension.
The patent includes claims covering certepetide’s chemical structure, pharmacokinetic properties, manufacturing methods, and its applications in treating solid tumor cancers.
A composition of matter patent protects the unique chemical structure of a substance and represents the strongest form of intellectual property protection.
The issuance of this patent expands Lisata’s intellectual property portfolio and grants exclusive rights to certepetide, restricting others from manufacturing or selling the drug.
“This new patent marks a key milestone, significantly boosting the value of both certepetide and the company by delaying generic encroachment for essentially the next two decades,” Lisata CEO Dr David Mazzo said.
“This extended patent protection aids our commercialization efforts by offering long-term market exclusivity and enhances the potential future development and commercialization of certepetide. It not only secures our IP but also greatly strengthens our negotiating position with potential partners, increasing the potential for sustained growth and value creation for our shareholders.”
Certepetide is a cyclic peptide designed to enhance the delivery of anti-cancer drugs to solid tumors by activating a tumor-specific uptake pathway, with additional potential to improve tumor response to immunotherapies.
It has shown favorable safety and clinical activity in trials and has received multiple US and EU regulatory designations, including Fast Track, Orphan Drug, and Rare Pediatric Disease designations.